FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 354:2443-2451 June 8, 2006 Number 23 Next

	Full Text PDF PDA Full Text PowerPoint Slide Set Editorial by Friedman, J.M. Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear PubMed Citation

ABSTRACT

Background Use of angiotensin-converting–enzyme (ACE) inhibitors during the second and third trimesters of pregnancy is contraindicated because of their association with an increased risk of fetopathy. In contrast, first-trimester use of ACE inhibitors has not been linked to adverse fetal outcomes. We conducted a study to assess the association between exposure to ACE inhibitors during the first trimester of pregnancy only and the risk of congenital malformations.

Methods We studied a cohort of 29,507 infants enrolled in Tennessee Medicaid and born between 1985 and 2000 for whom there was no evidence of maternal diabetes. We identified 209 infants with exposure to ACE inhibitors in the first trimester alone, 202 infants with exposure to other antihypertensive medications in the first trimester alone, and 29,096 infants with no exposure to antihypertensive drugs at any time during gestation. Major congenital malformations were identified from linked vital records and hospitalization claims during the first year of life and confirmed by review of medical records.

Results Infants with only first-trimester exposure to ACE inhibitors had an increased risk of major congenital malformations (risk ratio, 2.71; 95 percent confidence interval, 1.72 to 4.27) as compared with infants who had no exposure to antihypertensive medications. In contrast, fetal exposure to other antihypertensive medications during only the first trimester did not confer an increased risk (risk ratio, 0.66; 95 percent confidence interval, 0.25 to 1.75). Infants exposed to ACE inhibitors were at increased risk for malformations of the cardiovascular system (risk ratio, 3.72; 95 percent confidence interval, 1.89 to 7.30) and the central nervous system (risk ratio, 4.39; 95 percent confidence interval, 1.37 to 14.02).

Conclusions Exposure to ACE inhibitors during the first trimester cannot be considered safe and should be avoided.

Source Information

From the Departments of Pediatrics (W.O.C., S.D.), Biostatistics (P.G.A.), and Preventive Medicine (J.A.D., P.S.G., K.H., W.A.R.), Vanderbilt University School of Medicine, Nashville; and the Slone Epidemiology Center, Boston University, Boston (S.H.-D.).

Address reprint requests to Dr. Cooper at the Department of Pediatrics, Vanderbilt University School of Medicine, AA-0216 MCN, Nashville, TN 37232, or at william.cooper{at}vanderbilt.edu.

Full Text of this Article

Related Letters:

ACE Inhibitors and Major Congenital Malformations
Scialli A. R., Lione A., Sealey J. E., Itskovitz-Eldor J., Cooper W. O., Ray W. A.
Extract | Full Text | PDF  
N Engl J Med 2006; 355:1280-1281, Sep 21, 2006. Correspondence

This article has been cited by other articles:

• Balsells, M., Garcia-Patterson, A., Gich, I., Corcoy, R. (2009). Maternal and Fetal Outcome in Women with Type 2 Versus Type 1 Diabetes Mellitus: A Systematic Review and Metaanalysis. J. Clin. Endocrinol. Metab. 94: 4284-4291 [Abstract] [Full Text]  
• Raj, S. R., Stein, C. M., Saavedra, P. J., Roden, D. M. (2009). Cardiovascular Effects of Noncardiovascular Drugs. Circulation 120: 1123-1132 [Full Text]  
• Gipson, D. S., Massengill, S. F., Yao, L., Nagaraj, S., Smoyer, W. E., Mahan, J. D., Wigfall, D., Miles, P., Powell, L., Lin, J.-J., Trachtman, H., Greenbaum, L. A. (2009). Management of Childhood Onset Nephrotic Syndrome. Pediatrics 124: 747-757 [Abstract] [Full Text]  
• Caton, A. R., Bell, E. M., Druschel, C. M., Werler, M. M., Lin, A. E., Browne, M. L., McNutt, L.-A., Romitti, P. A., Mitchell, A. A., Olney, R. S., Correa, A., for the National Birth Defects Prevention Study, (2009). Antihypertensive Medication Use During Pregnancy and the Risk of Cardiovascular Malformations. Hypertension 54: 63-70 [Abstract] [Full Text]  
• Law, M R, Morris, J K, Wald, N J (2009). Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ 338: b1665-b1665 [Abstract] [Full Text]  
• Ionescu-Ittu, R., Marelli, A. J, Mackie, A. S, Pilote, L. (2009). Prevalence of severe congenital heart disease after folic acid fortification of grain products: time trend analysis in Quebec, Canada. BMJ 338: b1673-b1673 [Abstract] [Full Text]  
• RAMARAJ, R., SORRELL, V. L. (2009). Peripartum cardiomyopathy: Causes, diagnosis, and treatment. Cleveland Clinic Journal of Medicine 76: 289-296 [Abstract] [Full Text]  
• Day, C. J., Lipkin, G. W., Savage, C. O. S. (2009). Lupus nephritis and pregnancy in the 21st century. Nephrol Dial Transplant 24: 344-347 [Full Text]  
• Ringholm Nielsen, L., Damm, P., Mathiesen, E. R. (2009). Improved Pregnancy Outcome in Type 1 Diabetic Women With Microalbuminuria or Diabetic Nephropathy: Effect of intensified antihypertensive therapy?. Diabetes Care 32: 38-44 [Abstract] [Full Text]  
• Maynard, S. E., Thadhani, R. (2009). Pregnancy and the Kidney. J. Am. Soc. Nephrol. 20: 14-22 [Abstract] [Full Text]  
• Kolagasi, O., Sari, F., Akar, M., Sari, R. (2009). Normal Pregnancy and Healthy Child After Continued Exposure to Gliclazide and Ramipril During Pregnancy. The Annals of Pharmacotherapy 43: 147-149 [Abstract] [Full Text]  
• American Diabetes Association, (2009). Standards of Medical Care in Diabetes--2009. Diabetes Care 32: S13-S61 [Full Text]  
• Presbitero, P., Boccuzzi, G. G., Groot, C. J.M., Roos-Hesselink, J. W. (2009). CHAPTER 33 Pregnancy and Heart Disease. ESC Textbook of Cardiovascular Medicine 2: med-9780199566990-chapter-med-9780199566990-chapter [Abstract] [Full Text]  
• Warnes, C. A., Williams, R. G., Bashore, T. M., Child, J. S., Connolly, H. M., Dearani, J. A., del Nido, P., Fasules, J. W., Graham, T. P. Jr, Hijazi, Z. M., Hunt, S. A., King, M. E., Landzberg, M. J., Miner, P. D., Radford, M. J., Walsh, E. P., Webb, G. D. (2008). ACC/AHA 2008 Guidelines for the Management of Adults With Congenital Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Develop Guidelines on the Management of Adults With Congenital Heart Disease) Developed in Collaboration With the American Society of Echocardiography, Heart Rhythm Society, International Society for Adult Congenital Heart Disease, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J Am Coll Cardiol 52: e143-e263 [Full Text]  
• Warnes, C. A., Williams, R. G., Bashore, T. M., Child, J. S., Connolly, H. M., Dearani, J. A., del Nido, P., Fasules, J. W., Graham, T. P. Jr, Hijazi, Z. M., Hunt, S. A., King, M. E., Landzberg, M. J., Miner, P. D., Radford, M. J., Walsh, E. P., Webb, G. D. (2008). ACC/AHA 2008 Guidelines for the Management of Adults With Congenital Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Develop Guidelines on the Management of Adults With Congenital Heart Disease): Developed in Collaboration With the American Society of Echocardiography, Heart Rhythm Society, International Society for Adult Congenital Heart Disease, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. Circulation 118: e714-e833 [Full Text]  
• Keely, E (2008). Type 2 diabetes in pregnancy: importance of optimized care before, during and after pregnancy. Obstet Med 1: 72-77 [Abstract] [Full Text]  
• Khakoo, A. Y., Sidman, R. L., Pasqualini, R., Arap, W. (2008). Does the Renin-Angiotensin System Participate in Regulation of Human Vasculogenesis and Angiogenesis?. Cancer Res. 68: 9112-9115 [Abstract] [Full Text]  
• Nallamothu, B. K., Hayward, R. A., Bates, E. R. (2008). Beyond the Randomized Clinical Trial: The Role of Effectiveness Studies in Evaluating Cardiovascular Therapies. Circulation 118: 1294-1303 [Full Text]  
• Schwab, A. P. (2008). Epistemic Trust, Epistemic Responsibility, and Medical Practice. J Med Philos 33: 302-320 [Abstract] [Full Text]  
• Carroll, K. N., Arbogast, P. G., Dudley, J. A., Cooper, W. O. (2008). Increase in Incidence of Medically Treated Thyroid Disease in Children With Down Syndrome After Rerelease of American Academy of Pediatrics Health Supervision Guidelines. Pediatrics 122: e493-e498 [Abstract] [Full Text]  
• Roth, A., Elkayam, U. (2008). Acute myocardial infarction associated with pregnancy.. J Am Coll Cardiol 52: 171-180 [Abstract] [Full Text]  
• Coustan, D. R. (2008). A 40-Year-Old Woman With Diabetes Contemplating Pregnancy After Gastric Bypass Surgery. JAMA 299: 2550-2557 [Abstract] [Full Text]  
• (2008). Preconception care for women with diabetes. DTB 46: 36-40 [Abstract] [Full Text]  
• Kitzmiller, J. L., Block, J. M., Brown, F. M., Catalano, P. M., Conway, D. L., Coustan, D. R., Gunderson, E. P., Herman, W. H., Hoffman, L. D., Inturrisi, M., Jovanovic, L. B., Kjos, S. I., Knopp, R. H., Montoro, M. N., Ogata, E. S., Paramsothy, P., Reader, D. M., Rosenn, B. M., Thomas, A. M., Kirkman, M. S. (2008). Managing Preexisting Diabetes for Pregnancy: Summary of evidence and consensus recommendations for care. Diabetes Care 31: 1060-1079 [Full Text]  
• Guirguis, A. B., Malone, R. M., Chelminski, P. R., Pignone, M. (2008). Conception as a Potential Consequence of Diabetes Treatment. Clin. Diabetes 26: 83-84 [Full Text]  
• Podymow, T., August, P. (2008). Update on the Use of Antihypertensive Drugs in Pregnancy. Hypertension 51: 960-969 [Full Text]  
• Toh, S., Mitchell, A. A., Werler, M. M., Hernandez-Diaz, S. (2008). Toh et al. Respond to "Compromise or Compromising?". Am J Epidemiol 167: 644-645 [Full Text]  
• American Diabetes Association, (2008). Standards of Medical Care in Diabetes--2008. Diabetes Care 31: S12-S54 [Full Text]  
• Vaughan, T. B., Ovalle, F., Moreland, E. (2007). Vascular disease in paediatric type 2 diabetes: the state of the art. Diabetes and Vascular Disease Research 4: 297-304 [Abstract]  
• van Beynum, I.M., den Heijer, M., Blom, H.J., Kapusta, L. (2007). The MTHFR 677C->T polymorphism and the risk of congenital heart defects: a literature review and meta-analysis. QJM 100: 743-753 [Abstract] [Full Text]  
• Powrie, R. O. (2007). A 30-Year-Old Woman With Chronic Hypertension Trying to Conceive. JAMA 298: 1548-1558 [Abstract] [Full Text]  
• Schwarz, E. B., Postlethwaite, D. A., Hung, Y.-Y., Armstrong, M. A. (2007). Documentation of Contraception and Pregnancy When Prescribing Potentially Teratogenic Medications for Reproductive-Age Women. ANN INTERN MED 147: 370-376 [Abstract] [Full Text]  
• Ray, J. G., Vermeulen, M. J., Koren, G. (2007). Taking ACE inhibitors during early pregnancy: Is it safe?. cfp 53: 1439-1440 [Abstract] [Full Text]  
• El Sebaaly, Z., Charpentier, B., Snanoudj, R. (2007). Fetal malformations associated with mycophenolate mofetil for lupus nephritis. Nephrol Dial Transplant 22: 2722-2722 [Full Text]  
• Wosik, K., Cayrol, R., Dodelet-Devillers, A., Berthelet, F., Bernard, M., Moumdjian, R., Bouthillier, A., Reudelhuber, T. L., Prat, A. (2007). Angiotensin II Controls Occludin Function and Is Required for Blood Brain Barrier Maintenance: Relevance to Multiple Sclerosis. J. Neurosci. 27: 9032-9042 [Abstract] [Full Text]  
• Frye, R. L. (2007). Update in Cardiology. ANN INTERN MED 147: 180-186 [Full Text]  
• Harrington, D. W., Munekata, M. T. (2007). Update in General Internal Medicine. ANN INTERN MED 147: 104-116 [Full Text]  
• Raebel, M. A., Carroll, N. M., Kelleher, J. A., Chester, E. A., Berga, S., Magid, D. J. (2007). Randomized Trial to Improve Prescribing Safety During Pregnancy. J. Am. Med. Inform. Assoc. 14: 440-450 [Abstract] [Full Text]  
• Jenkins, K. J., Correa, A., Feinstein, J. A., Botto, L., Britt, A. E., Daniels, S. R., Elixson, M., Warnes, C. A., Webb, C. L. (2007). Noninherited Risk Factors and Congenital Cardiovascular Defects: Current Knowledge: A Scientific Statement From the American Heart Association Council on Cardiovascular Disease in the Young: Endorsed by the American Academy of Pediatrics. Circulation 115: 2995-3014 [Abstract] [Full Text]  
• Aguiar-Souto, P., Mirelis, J. G., Silva-Melchor, L. (2007). Guidelines on the management of valvular heart disease. Eur Heart J 28: 1267-1267 [Full Text]  
• Herse, F., Dechend, R., Harsem, N. K., Wallukat, G., Janke, J., Qadri, F., Hering, L., Muller, D. N., Luft, F. C., Staff, A. C. (2007). Dysregulation of the Circulating and Tissue-Based Renin-Angiotensin System in Preeclampsia. Hypertension 49: 604-611 [Abstract] [Full Text]  
• Seely, E. W., Maxwell, C. (2007). Chronic Hypertension in Pregnancy. Circulation 115: e188-e190 [Full Text]  
• Szmitko, P. E, Juurlink, D. (2007). Fetal exposure to ACE inhibitors increased risk of major congenital malformations. Evid. Based Med. 12: 26-26 [Full Text]  
• Marelli, A. J., Mackie, A. S., Ionescu-Ittu, R., Rahme, E., Pilote, L. (2007). Congenital Heart Disease in the General Population: Changing Prevalence and Age Distribution. Circulation 115: 163-172 [Abstract] [Full Text]  
• Gelson, E., Johnson, M., Gatzoulis, M., Uebing, A. (2007). Cardiac disease in pregnancy. Part 1: congenital heart disease. The Obstetrician and Gynaecologist 9: 15-20 [Abstract] [Full Text]  
• Murphy, H. R, Temple, R. C, Roland, J. M (2007). Improving outcomes of pregnancy for women with type 1 and type 2 diabetes. British Journal of Diabetes & Vascular Disease 7: 38-42 [Abstract]  
• American Diabetes Association, (2007). Standards of Medical Care in Diabetes--2007. Diabetes Care 30: S4-S41 [Full Text]  
• (2006). Teratogenicity of first trimester ACE inhibitors. Arch. Dis. Child. 91: 840-840 [Full Text]  
• Scialli, A. R., Lione, A., Sealey, J. E., Itskovitz-Eldor, J., Cooper, W. O., Ray, W. A. (2006). ACE inhibitors and major congenital malformations.. NEJM 355: 1280-1280 [Full Text]  
• Malik, I. (2006). JournalScan. Heart 92: 1360-1360 [Full Text]  
• (2006). ACE Inhibitors Increase Risk for Congenital Anomalies in the First Trimester, Too. JWatch Pediatrics 2006: 1-1 [Full Text]  
• Beckley, E. T. (2006). ACE Inhibitors May Increase Risk of Birth Defects. DOC News 3: 13-13 [Full Text]  
• Malik, I. (2006). JournalScan. Heart 92: 1183-1184 [Full Text]  
• (2006). ACE Inhibitors and Birth Defects: Unsafe in Any Trimester. JWatch Women's Health 2006: 1-1 [Full Text]  
• (2006). ACE Inhibitors Are Teratogenic in the First Trimester. Journal Watch Cardiology 2006: 1-1 [Full Text]  
• (2006). Safety of First-Trimester Exposure to ACE Inhibitors. JWatch General 2006: 3-3 [Full Text]  
• Fister, K. (2006). What's new in the other general journals.. BMJ 332: 1442-1443 [Full Text]  
• Friedman, J.M. (2006). ACE inhibitors and congenital anomalies.. NEJM 354: 2498-2500 [Full Text]